SEC Form 4 · accession 0001209191-17-005333
Outlook Therapeutics, Inc. · OTLK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kurt J Hilzinger
Director
Period of report
Jan 23, 2017
Accepted (ET)
Jan 24, 2017 · 5:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001649989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 23, 2017 | X | 12,036 | $0.01 | A | 30,554 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (Right to Buy)F2 | $0.01 | Jan 23, 2017 | X | 12,036 | D | — | Nov 8, 2019 | Common Stock | 12,036 | 0 | D |
Explanation of responses
- F1Represents the exercise of (i) a Warrant to purchase 7,561 received from Proximare Lifesciences Fund LLC, of which the reporting person is a member, and (ii) a Warrant to purchase 4,475 received from Proximare Lifesciences Fund 2 LLC, of which the reporting person is a member.
- F2Immediately exercisable.